Haemonetics stock surges 17% on CSL Plasma supply deal update
Haemonetics (HAE) shares rose 17% premarket after CSL Plasma updated its supply agreement rollout timeline. CSL expects to complete the rollout of Haemonetics' NexSys PCS devices by the end of 2027. The companies initially agreed in August 2026, with CSL potentially using Haemonetics' devices and disposables in the U.S. Haemonetics did not update its fiscal 2027 guidance.
How this was made
The 30-second read
Why it matters
The updated supply agreement signals a longer‑term revenue stream, justifying the stock's sharp move.
Market read
The news triggered a 17% pre‑market surge, indicating immediate trading relevance.
What to watch
The agreement is non‑exclusive and subject to change; revenue impact remains uncertain until Q2 earnings call.
Background
Haemonetics supplies plasma collection devices; CSL Plasma is a major U.S. plasma operator.
Ticker impact
Shares jumped over 17% pre‑market after Haemonetics disclosed an updated supply agreement rollout with CSL Plasma.
likely upward pressure as the market prices in higher future sales from the CSL deal
A 17% pre‑market surge on fresh contract news indicates strong trader conviction; the rollout is expected to span U.S. plasma centers through 2027.
Market effects
May lift other plasma‑collection equipment suppliers and related biotech service providers.
Positive for U.S. healthcare equipment sector.
Limited to U.S. plasma industry; no broad macro effect.
Counterpoint
If rollout delays occur, the rally could reverse; investors should watch for execution updates.
Key entities
- companyHaemonetics Corporation
Provider of plasma collection equipment.
- companyCSL Plasma Inc.
U.S. plasma collection subsidiary of CSL.
